Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2012 (2012), Article ID 364684, 12 pages
http://dx.doi.org/10.1155/2012/364684
Research Article

A Possible Novel Anti-Inflammatory Mechanism for the Pharmacological Prolyl Hydroxylase Inhibitor 3,4-Dihydroxybenzoate: Implications for Use as a Therapeutic for Parkinson’s Disease

Buck Institute for Research on Aging, 8001 Redwood Boulevard, Novato, CA 94945, USA

Received 8 December 2011; Revised 8 March 2012; Accepted 9 March 2012

Academic Editor: Carlos Barcia

Copyright © 2012 Shankar J. Chinta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. K. Andersen, “Oxidative stress in neurodegeneration: cause or consequence?” Nature Medicine, vol. 10, supplement, pp. S18–S25, 2004. View at Google Scholar · View at Scopus
  2. A. H. Schapira and P. Jenner, “Etiology and pathogenesis of Parkinson's disease,” Movement Disorders, vol. 26, no. 6, pp. 1049–1055, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Thomas and M. F. Beal, “Parkinson's disease,” Human Molecular Genetics, vol. 16, no. 2, pp. R183–R194, 2007. View at Google Scholar
  4. A. Gupta, V. L. Dawson, and T. M. Dawson, “What causes cell death in Parkinson's disease?” Annals of Neurology, vol. 64, supplement 2, pp. S3–S15, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Minghetti, “Role of inflammation in neurodegenerative diseases,” Current Opinion in Neurology, vol. 18, no. 3, pp. 315–321, 2005. View at Google Scholar · View at Scopus
  6. W. Kuhn, T. Müller, I. Nastos, and D. Poehlau, “The neuroimmune hypothesis in Parkinson's disease,” Reviews in the Neurosciences, vol. 8, no. 1, pp. 29–34, 1997. View at Google Scholar · View at Scopus
  7. P. L. McGeer, S. Itagaki, B. E. Boyes, and E. G. McGeer, “Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains,” Neurology, vol. 38, no. 8, pp. 1285–1291, 1988. View at Google Scholar · View at Scopus
  8. C. F. Orr, D. B. Rowe, and G. M. Halliday, “An inflammatory review of Parkinson's disease,” Progress in Neurobiology, vol. 68, no. 5, pp. 325–340, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. M. G. Tansey, M. K. McCoy, and T. C. Frank-Cannon, “Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention,” Experimental Neurology, vol. 208, no. 1, pp. 1–25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. E. C. Hirsch and S. Hunot, “Neuroinflammation in Parkinson's disease: a target for neuroprotection?” The Lancet Neurology, vol. 8, no. 4, pp. 382–397, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Knott, G. Stern, and G. P. Wilkin, “Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2,” Molecular and Cellular Neuroscience, vol. 16, no. 6, pp. 724–739, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. G. W. Kreutzberg, “Microglia: a sensor for pathological events in the CNS,” Trends in Neurosciences, vol. 19, no. 8, pp. 312–318, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Qian, P. M. Flood, and J. S. Hong, “Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy,” Journal of Neural Transmission, vol. 117, no. 8, pp. 971–979, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. K. Lee, T. Tran, and M. G. Tansey, “Neuroinflammation in Parkinson's disease,” Journal of Neuroimmune Pharmacology, vol. 4, no. 4, pp. 419–429, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Liu and J. S. Hong, “Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention,” Journal of Pharmacology and Experimental Therapeutics, vol. 304, no. 1, pp. 1–7, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. A. C. R. Epstein, J. M. Gleadle, L. A. McNeill et al., “C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation,” Cell, vol. 107, no. 1, pp. 43–54, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Hirsilä, P. Koivunen, V. Günzler, K. I. Kivirikko, and J. Myllyharju, “Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor,” The Journal of Biological Chemistry, vol. 278, no. 33, pp. 30772–30780, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. G. L. Semenza, “HIF-1, O2, and the 3 PHDs: how animal cells signal hypoxia to the nucleus,” Cell, vol. 107, no. 1, pp. 1–3, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. P. D. Hurn, R. C. Koehler, K. K. Blizzard, R. J. Traystman, and J. S. Beckman, “Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs,” Stroke, vol. 26, no. 4, pp. 688–695, 1995. View at Google Scholar · View at Scopus
  20. A. Siddiq, I. A. Ayoub, J. C. Chavez et al., “Hypoxia-inducible factor prolyl 4-hydroxylase inhibition: a target for neuroprotection in the central nervous system,” The Journal of Biological Chemistry, vol. 280, no. 50, pp. 41732–41743, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. D. W. Lee, S. Rajagopalan, A. Siddiq et al., “Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Model for the potential involvement of the hypoxia-unducible factor pathway in Parkinson disease,” The Journal of Biological Chemistry, vol. 284, no. 42, pp. 29065–29076, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Blasi, R. Barluzzi, V. Bocchini, R. Mazzolla, and F. Bistoni, “Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus,” Journal of Neuroimmunology, vol. 27, no. 2-3, pp. 229–237, 1990. View at Google Scholar · View at Scopus
  23. S. J. Chinta, S. Rajagopalan, D. A. Butterfield, and J. K. Andersen, “In vitro and in vivo neuroprotection by γ-glutamylcysteine ethyl ester against MPTP: relevance to the role of glutathione in Parkinson's disease,” Neuroscience Letters, vol. 402, no. 1-2, pp. 137–141, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. S. J. Chinta, A. Rane, K. S. Poksay, D. E. Bredesen, J. K. Andersen, and R. V. Rao, “Coupling endoplasmic reticulum stress to the cell death program in dopaminergic cells: effect of paraquat,” NeuroMolecular Medicine, vol. 10, no. 4, pp. 333–342, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Sriram, D. B. Miller, and J. P. O'Callaghan, “Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-α,” Journal of Neurochemistry, vol. 96, no. 3, pp. 706–718, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Kaku, T. Shikimi, Y. Kamisaki et al., “Elevation of striatal interleukin-6 and serum corticosterone contents in MPTP-treated mice,” Clinical and Experimental Pharmacology and Physiology, vol. 26, no. 9, pp. 680–683, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Peng, X. O. Mao, F. F. Stevenson, M. Hsu, and J. K. Andersen, “The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway,” The Journal of Biological Chemistry, vol. 279, no. 31, pp. 32626–32632, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Wang, H. Wang, H. Guo, L. Kang, X. Gao, and L. Hu, “Neuroprotection of Scutellarin is mediated by inhibition of microglial inflammatory activation,” Neuroscience, vol. 185, pp. 150–160, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. J. K. Mallajosyula, D. Kaur, S. J. Chinta et al., “MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology,” PLoS One, vol. 3, no. 2, Article ID e1616, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. J. S. Jung, J. A. Shin, E. M. Park et al., “Anti-inflammatory mechanism of ginsenoside Rh1 in lipopolysaccharide- stimulated microglia: critical role of the protein kinase A pathway and hemeoxygenase-1 expression,” Journal of Neurochemistry, vol. 115, no. 6, pp. 1668–1680, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Paine, B. Eiz-Vesper, R. Blasczyk, and S. Immenschuh, “Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential,” Biochemical Pharmacology, vol. 80, no. 12, pp. 1895–1903, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. C. M. Long-Smith, A. M. Sullivan, and Y. M. Nolan, “The influence of microglia on the pathogenesis of Parkinson's disease,” Progress in Neurobiology, vol. 89, no. 3, pp. 277–287, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Li, S. Zhu, C. Wu, C. Yan, Y. Liu, and L. Shugan, “Neuroinflammation and cell therapy for Parkinson's disease,” Frontiers in Bioscience, vol. 3, pp. 1407–1420, 2011. View at Google Scholar
  34. M. G. Tansey and M. S. Goldberg, “Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention,” Neurobiology of Disease, vol. 37, no. 3, pp. 510–518, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. N. R. Bhat, P. Zhang, J. C. Lee, and E. L. Hogan, “Extracellular signal-regulated kinase and p38 subgroups of mitogen- activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-α gene expression in endotoxin-stimulated primary glial cultures,” Journal of Neuroscience, vol. 18, no. 5, pp. 1633–1641, 1998. View at Google Scholar · View at Scopus
  36. Z. Xie, C. J. Smith, and L. J. Van Eldik, “glias induce neuron death via MAP kinase signaling pathways involving JNK and p38,” Glia, vol. 45, no. 2, pp. 170–179, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Koistinaho, M. I. Kettunen, G. Goldsteins et al., “β-amyloid precursor protein transgenic mice that harbor diffuse Aβ deposits but do not form plaques show increased ischemic vulnerability: role of inflammation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 3, pp. 1610–1615, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Shibata, H. Katsuki, M. Nishiwaki, T. Kume, S. Kaneko, and A. Akaike, “Lipopolysaccharide-induced dopaminergic cell death in rat midbrain slice cultures: role of inducible nitric oxide synthase and protection by indomethacin,” Journal of Neurochemistry, vol. 86, no. 5, pp. 1201–1212, 2003. View at Google Scholar · View at Scopus
  39. M. M. Iravani, K. Kashefi, P. Mander, S. Rose, and P. Jenner, “Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration,” Neuroscience, vol. 110, no. 1, pp. 49–58, 2002. View at Google Scholar
  40. G. T. Liberatore, V. Jackson-Lewis, and S. Vukosavic, “Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease,” Nature Medicine, vol. 5, no. 12, pp. 1403–1409, 1999. View at Publisher · View at Google Scholar
  41. D. Nowis, M. Bugajski, M. Winiarska et al., “Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice,” BMC Cancer, vol. 8, article 197, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. S. W. Ryter, J. Alam, and A. M. K. Choi, “Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications,” Physiological Reviews, vol. 86, no. 2, pp. 583–650, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. J. R. Scott, B. Y. Chin, M. H. Bilban, and L. E. Otterbein, “Restoring HOmeostasis: is heme oxygenase-1 ready for the clinic?” Trends in Pharmacological Sciences, vol. 28, no. 5, pp. 200–205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. G. S. Jeong, B. Li, D. S. Lee et al., “Lavandulyl flavanones from Sophora flavescens protect mouse hippocampal cells against glutamate-induced neurotoxicity via the induction of heme oxygenase-1,” Biological and Pharmaceutical Bulletin, vol. 31, no. 10, pp. 1964–1967, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Y. Lu, Y. Y. Tsao, Y. M. Leung, and K. P. Su, “Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: implications of antidepressant effects for omega-3 fatty acids,” Neuropsychopharmacology, vol. 35, no. 11, pp. 2238–2248, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. K. J. Min, M. S. Yang, S. U. Kim, I. Jou, and E. H. Joe, “Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation,” Journal of Neuroscience, vol. 26, no. 6, pp. 1880–1887, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Kitamura, J. I. Kakimura, Y. Matsuoka, Yasuyuki Nomura, P. J. Gebicke-Haerter, and T. Taniguchi, “Activators of peroxisome proliferator-activated receptor-γ (PPARγ) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells,” Neuroscience Letters, vol. 262, no. 2, pp. 129–132, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Tsoyi, H. J. Kim, J. S. Shin et al., “HO-1 and JAK-2/STAT-1 signals are involved in preferential inhibition of iNOS over COX-2 gene expression by newly synthesized tetrahydroisoquinoline alkaloid, CKD712, in cells activated with lipopolysacchride,” Cellular Signalling, vol. 20, no. 10, pp. 1839–1847, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Vareille, F. Rannou, N. Thélier et al., “Heme oxygenase-1 is a critical regulator of nitric oxide production In Enterohemorrhagic Escherichia coli-infected human enterocytes1,” The Journal of Immunology, vol. 180, no. 8, pp. 5720–5726, 2008. View at Google Scholar · View at Scopus